InvestmentNov 9, 2026, 09:11 AM
NewcelX Prices $1.55M Equity Financing at 20% Premium
AI Summary
NewcelX Ltd. announced the pricing of a $1.55 million private placement equity financing. The shares were sold at a 20% premium to the market price, indicating strong investor confidence. The funds raised will be used to advance the company's lead program, NCEL-101, for type 1 diabetes, including initiating FDA-required studies and preparing for Phase 1/2a clinical trials. The financing was led by international healthcare investors and The Crushing T1 Foundation.
Key Highlights
- NewcelX Ltd. priced a private placement equity financing of $1.55 million.
- The financing was conducted at a purchase price of $3.29 per share, a 20% premium to the market price.
- The company is selling 471,125 common shares and warrants to purchase 353,344 common shares.
- Proceeds will fund IND-enabling toxicology studies for NCEL-101, advance manufacturing, and prepare for Phase 1/2a trials.
- The offering includes participation from international healthcare investors and The Crushing T1 Foundation.
Price Impact
More from NCEL